As new immunotherapeutic agents are being rapidly adopted in many cancers including NPC, promising response rates to the anti-programmed cell death-1 (PD1)-targeted therapy in the heavily pretreated NPC patients with locally recurrent disease have been demonstrated [124,125,126]. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.